Cgp 6809 is a new methylnitrosoureido-sugar analogue that has been shown to be active against a broad spectrum of transplantable tumours in mice and rats. CGP 6809 is a promising new agent for clinical trials, especially for large bowel and epidermoid lung cancer. References: Creaven PJ, Cowens JW, Huben R, Petrelli N, Karakousis C, Traynor D. Phase I trial of a new nitrosourea, CGP 6809, given every 2 weeks. Cancer Chemother Pharmacol. 1989;23(4):266-7. PubMed PMID: 2924383.

纯度：≥98%

CAS：84069-38-5